Omentin-1 vs Insulin Degludec
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Insulin Degludec (Insulin degludec (desB30, acylated ultra-long-acting insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Insulin Degludec |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Insulin degludec (desB30, acylated ultra-long-acting insulin analog) |
| Molecular Weight | ~35 kDa | 6103.9 Da |
| Half-Life | hours | More than 25 hours |
| Amino Acids | 313 | 50 |
| Typical Dose | No approved human dose; research use only | 0.1-0.2 U/kg once daily |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 7000 |
| Research Status | Pre-clinical | Approved |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Insulin Degludec Benefits
- ✓Ultra-long basal coverage
- ✓Lower day-to-day variability
- ✓Reduced nocturnal hypoglycemia
- ✓Flexible dosing time
Omentin-1 Dosing
not established|not established
Insulin Degludec Dosing
Inject SC once daily|Titrate to fasting glucose and HbA1c response|May be administered with flexible timing in adults
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Degludec Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Insulin Degludec
Studies highlight prolonged action and lower glycemic variability compared with many other basal insulins. It is frequently used in research on ultra-long basal coverage and hypoglycemia reduction.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.